TPM3 and neoplasm: In this report, we successfully established patient tumor cells from a TPM3-NTRK1 fusion CRC patient and demonstrated that these cells were potently inhibited by entrectinib at an IC50 of 8.2nM in the conventional MTT assay and 89 nM in 3-dimentional high throughput drug screening system.